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Abstract
Background: Acute viral bronchiolitis is one of the most common causes of hospitalisation during
infancy in our region with respiratory syncytial virus (RSV) historically being the major causative
agent. Many infants with early-life RSV bronchiolitis have sustained bronchial hyperreactivity for
many years after hospitalisation and the reasons for this are probably multifactorial. The principal
aim of the present study was to investigate if children hospitalised for any acute viral bronchiolitis
during infancy in our region, and not only those due to RSV, had more episodes of subsequent
wheezing up to age seven years and reduced lung function at that age compared to children not
hospitalised for acute bronchiolitis during infancy. A secondary aim was to compare the
hospitalised infants with proven RSV bronchiolitis (RS+) to the hospitalised infants with non-RSV
bronchiolitis (RS-) according to the same endpoints.
Methods: 57 infants hospitalised at least once with acute viral bronchiolitis during two consecutive
winter seasons in 1993–1994 were examined at age seven years. An age-matched control group of
64 children, who had not been hospitalised for acute viral bronchiolitis during infancy, were
recruited from a local primary school. Epidemiological and clinical data were collected
retrospectively from hospital discharge records and through structured clinical interviews and
physical examinations at the follow-up visit.
Results: The children hospitalised for bronchiolitis during infancy had decreased lung function,
more often wheezing episodes, current medication and follow-up for asthma at age seven years
than did the age matched controls. They also had lower average birth weight and more often first
order family members with asthma. We did not find significant differences between the RSV+ and
RSV- groups.
Conclusion:  Children hospitalised for early-life bronchiolitis are susceptible to recurrent
wheezing and reduced pulmonary function by seven years compared to age-matched children not
hospitalised for early-life bronchiolitis. We propose that prolonged bronchial hyperreactivity could
follow early-life RSV negative as well as RSV positive bronchiolitis.
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Background
Acute viral bronchiolitis is one of the most common
causes of hospitalisation during infancy in Akershus
County, Norway, with respiratory syncytial virus (RSV)
historically being the major causative agent. RSV causes
respiratory disease in young children worldwide and by
the age of two years most children have been infected. In
temperate climates the infection occurs as yearly winter
epidemics and the impact of RSV on human health is
demonstrated annually when infants are admitted to hos-
pitals in large numbers. Symptoms vary from a mild
upper respiratory tract infection to severe bronchiolitis
with hyperinflated lungs and hypoxemia [1]. The first
infection is usually the most severe but milder reinfec-
tions are common throughout life. The risk of severe ill-
ness is highest in infants born prematurely and in those
with chronic lung disease, certain congenital heart defects
and immunodeficiency disorders [2,3]. Many infants with
severe RSV bronchiolitis experience recurrent wheezing in
later childhood and there is growing evidence that early-
life RSV bronchiolitis may predispose some infants to the
development of childhood asthma [4-6]. The genetic
background of the infant, intermittent changes in host cel-
lular immune responses and neural control leading to sus-
tained bronchial hyperreactivity and recurrent wheezing,
timing of RSV infection with respect to allergen exposure,
environmental conditions and exposure to endotoxin are
all factors suggested to contribute to RSV induced asthma
[7-9].
Human metapneumovirus (hMPV) is now recognised as
one of several other viral pathogens that can cause acute
bronchiolitis, the remaining being mainly rhinovirus,
parainfluenzavirus, influenzavirus and adenovirus [10].
hMPV have recently been found to be an important cause
of acute bronchiolitis in infants and children. However,
the long-term effect of this and other viral agents on lung
function and symptoms in later childhood is not yet fully
investigated [11,12].
The primary aim of this study was to compare the airway
symptoms and lung function of children hospitalised for
early-life bronchiolitis with age matched controls without
such a history at age seven years. We also aimed to
describe possible differences between those with proven
RSV bronchiolitis and those with non-RSV bronchiolitis
regarding the same endpoints.
Methods
Study population
During two consecutive years in 1993–1994 a sample of
nasopharyngeal aspirate (NPA) was collected from infants
hospitalised with acute respiratory disease. The doctors on
call conducted, as part of the admission routine, clinical
interviews using structured questionnaires and performed
physical examination of all infants admitted with sus-
pected acute bronchiolitis.
In the present follow-up study at age seven years hospital
records, questionnaires and microbiological results of all
children hospitalised during infancy with acute bronchi-
olitis were analysed in retrospect. 109 infants presenting
with respiratory insufficiency such as tachypnoe, intercos-
tal retractions, increased mucus production and soar
coughing were eligible for follow-up. However, we
excluded 11 infants who were born before completed 37
wGA (weeks of gestational age), 11 infants who had diver-
gent results in two different microbiological tests, 22
infants who had insufficient NPA material for testing, two
children who had died from unrelated causes and six chil-
dren that did not want to participate or had moved far
away from our region.
The remaining 57 children were willing and able to take
part in the study and came for a follow-up visit at age
seven years. Children hospitalised during infancy with
verified RSV bronchiolitis (RS+) had to be positive for RSV
in two different microbiological tests, and children hospi-
talised with non-RSV bronchiolitis (RS-) had to be nega-
tive for RSV in the same two different microbiological
tests.
Microbiological tests
Two different tests for detection of RSV in NPA were used.
These were our own in-house Abbott TestPack RSV
enzyme immunoassay (EIA) and immunofluorescens (IF)
staining performed in our reference laboratory at the
Department of Microbiology, Rikshospitalet, Oslo
[13,14].
Structured clinical interview at the follow-up visit
A clinical interview based on the structured questionnaire
used when the children with bronchiolitis were admitted
to hospital were performed by three of the authors in the
study (H.O.F, T.F., G.R.) to give information on episodes
of wheezing (defined by us as episodes of difficult breath-
ing accompanied by a whistling noise in the chest during
expiration), number of visits to a family physician, prac-
ticing paediatrician and resubmissions to any hospital for
wheezing or asthma (as diagnosed by a medical doctor)
during the 6–7 years that had passed since the hospitalisa-
tion in infancy. Hospital records confirmed number of
hospitalisations, whereas the parents gave information
regarding visits to a family physician or practicing paedia-
trician. Information on failure to thrive, regular medica-
tions and physical activity was given in the interviews, as
was information on parental smoking habits, number of
preschool (<6 years old) siblings and prevalence of
allergy, eczema and asthma in first order family membersBMC Pediatrics 2005, 5:31 http://www.biomedcentral.com/1471-2431/5/31
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(mother, father or siblings) that had been diagnosed by a
medical doctor.
Physical examination and pulmonary function tests at the 
follow-up visit
The medical doctors who conducted the structured clini-
cal interviews performed weight and height measure-
ments and a general clinical examination including
inspection and auscultation at the follow-up visit. All chil-
dren performed a standard pulmonary function test (PFT)
under the supervision and guidance of a skilled paediatric
nurse (G.K.U.). Forced vital capacity (FVC), forced expira-
tory volume in one second (FEV1) and forced expiratory
flow rate at 50% of FVC (FEF50) were measured with the
Vmax 20 equipment (SensorMedics). The equipment was
calibrated daily according to the specifications of the pro-
ducer. Measurements of pulmonary function were per-
formed both before and 10 minutes after inhalation of 0,2
mg salbutamol (Airomir Autohaler) and the one attempt
(out of three) with the best technical profile both before
and after salbutamol was used for analysis.
The control group
An age-matched control group of seven years old children
were recruited from a nearby primary school. A letter was
distributed by the school principal to the parents of 92
children (three school classes) providing information
about the study and explaining the criteria set for partici-
pation. All children had to be healthy term infants born at
completed 37 wGA and without history of hospitalisation
for respiratory problems during the first year of life. 64
children fulfilled the inclusion criteria, gave informed
consents and took part in the study. At the follow-up visit
the inclusion criteria were confirmed, an identical struc-
tured clinical interview with the parents of the control
children were undertaken and the children performed the
same PFT as the other children in the study.
Statistics
For comparison of continuous data between two groups
the independent samples T-test was used and for compar-
ison of ordinal and nominal data between two groups we
used chi square tests. A p-value <0.05 was considered sta-
tistically significant and continuous data were given with
95% confidence intervals (CI). The statistical programme
SPSS, version 12.0.1, was used in all calculations.
Ethics
The regional ethics committee for medical research
approved the study and the parents gave oral and written
informed consent.
Results
Structured clinical interviews
Among the 57 children hospitalised with acute bronchi-
olitis in infancy, 35 children (61%) tested double RSV
positive while 22 (39%) tested double negative for RSV in
NPA. Mean birth weight, mean age at hospitalisation and
mean length of hospitalisation including admission day
were not significantly different between these groups.
According to data collected at admission, seven (32%) in
the RS- and 15 (43%) in the RS+ group had experienced
one or more episodes of a possible lower respiratory tract
infection prior to the first hospitalisation for
bronchiolitis.
There were not significant differences between the RS- and
RS+ group or between these two groups combined and the
control group regarding gender, weight or height at the
follow-up visit. Mean birth weight was significantly lower
in the hospitalised group compared to the control group
(tab 1). First order family members of the hospitalised
children had significantly higher prevalence of asthma
than first order family members of the control group
(39% vs 19%, p = 0.015), while no significant differences
were observed for other risk factors (tab 1). Within the
hospitalised groups no significant differences were found
for any of the risk factors (tab 2).
In the group of children hospitalised with acute bronchi-
olitis in infancy 32 subsequent hospitalisations in 24 chil-
dren were noted with peak incidence in the first year of
life. Only one child in the control group needed hospital-
isation for wheezing during the study period (fig 1).
29 children in the hospitalised group were reported with
≥3 episodes of wheezing during the follow-up period
compared to 9 children in the control group (51% vs
14%, p < 0.001). No significant differences were found
between the RS+ and RS- groups in this respect (tab 3).
At the follow-up visit 31 children in the hospitalised
group were currently under supervision for asthma by a
practicing paediatrician or a family physician, in contrast
to five children in the control group (54% vs 8%, p <
0.001). More children in the hospitalised group than in
the control group used asthma medication currently (35%
vs 8%, p < 0.01). No statistical differences were found
between the RS+ and RS- groups for these parameters (tab
3).
Pulmonary function tests
No differences were found between the RS+ and RS-
groups for FVC, FEV1 and FEF50 when comparing pre-
dicted values and test results before and after inhalation of
salbutamol (tab 4). The test results for FVC after salbuta-
mol, FEV1 before salbutamol and FEF50 before and afterBMC Pediatrics 2005, 5:31 http://www.biomedcentral.com/1471-2431/5/31
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salbutamol were significantly worse in the combined hos-
pitalised group than in the control group (tab 4). We did
not find differences between groups for reversibility when
measured as percent improvement from baseline after
inhalation of salbutamol for any of the test parameters
(tab 4).
We also performed all analyses excluding the children
with prior infection, first from the RS- group, then from
both groups. There were not any substantial changes in
observations or conclusions. These data are not shown.
Discussion
The results of this follow-up study show that children hos-
pitalised with acute bronchiolitis during infancy in our
region are at increased risk for subsequent childhood
wheezing and for reduced pulmonary function, at least up
to age seven years. The children were all admitted to the
same hospital and from two consecutive winter seasons.
Mean length of hospitalisation including admission day is
in accordance with other studies [15]. Mean age at first
hospitalisation is higher than in other studies, and 39% of
Table 1: Follow-up of children hospitalised or not with acute bronchiolitis in infancy
Reported at child age seven years Hospitalised group Not hospitalised 
group
RS- (n = 22) RS+ (n = 35) 95% CIa Both (n = 57) Controls (n = 64) 95% CIa
Age, mean (range) at 
hospitalisation, months
5.9 (0–11) 5.1 (0–9) -0.8 2.5
Length, mean (range) of 
hospitalisation, days
4.6 (2–20) 4.8 (2–14) -2.1 1.8
Birth weight, mean (range), 
gramsb
3507 (2420–4300) 3506 (2500–4045) -225.6 228.5 3506 (2420–4300) 3733 (2100–5220) -425.2 -27.7
Weight, mean (range) at follow-
up visit, kg
27.5 (23–42) 28.3 (22–53) -4.0 2.4 28.0 (22–53) 29.2 (20–45) -0.8 3.2
Height, mean (range) at follow-up 
visit, cm
127.7 (118–139) 127.3 (117–146) -2.8 3.7 127.4 (117–146) 128.6 (115–145) -1.0 3.4
Age, mean (range) at follow-up 
visit, months
93.6 (86–101) 92.8 (86–102) -1.2 2.9 93.1 (86–102) 94.0 (88–99) -0.4 2.2
No. boys (%) 12 (54) 20 (57) 32 (56) 36 (56)
a 95% confidence interval (CI) of difference between means
b P = 0.023 with independent samples T-test between the hospitalised and not hospitalised group
Table 2: Risk factors in family members of children hospitalised or not with acute bronchiolitis in infancy
Reported at child age seven years Hospitalised group Not hospitalised group
No. families with risk factorsa RS- (n = 22) RS+ (n = 35) Both (n = 57) Controls (n = 64)
Allergy before seven years 8 13
Current allergy 12 16 28 33
Eczema before seven years 6 7
Current eczema 8 14 22 28
Asthma before seven years 10 8
Current asthmab 10 12 22 12
Siblings <6 years before seven years 12 22
Current siblings <6 years 6 11 17 26
Parental smoking before seven years 10 16
Current parental smoking 10 19 29 28
a Risk factors in first order family members (mother, father, siblings) as reported by parents
b P = 0.015 with chi square test between the hospitalised group and not hospitalised groupBMC Pediatrics 2005, 5:31 http://www.biomedcentral.com/1471-2431/5/31
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the children had experienced episodes of possible RSV
infections before hospitalisation [16,17]. These children
were not unevenly distributed on the RS+ and RS- groups.
We were not able to observe substantial changes in the
results when excluding children with prior infections. This
is not surprising. First, since the number of observations is
reduced by this procedure, larger differences are necessary
to provide significant changes. Secondly, none of these
prior infections were severe enough to require admission
to hospital. Accordingly, they did probably not meet the
criteria of Ruuskanen and Ogra [18] or Court [19], and we
assume it rather unlikely that they were due to RSV. Nev-
ertheless, there is a small possibility that we have underes-
timated differences between the RS negative and positive
groups.
We were surprised to find that many of the hospitalised
children were deemed RSV negative in NPA, since they
were examined in the middle of an RSV epidemic. Obvi-
ously, the two microbiological techniques used in our
study may not have been sensitive and specific enough
due to properties of the tests themselves [20]. In 1993–
1994 we did not have access to more sensitive microbio-
logical tests, such as detection of nucleic acid by reverse-
transcriptase polymerase chain reaction (PCR) [21]. How-
ever, using new knowledge about the performance of the
tests we used compared to PCR [22,23], we have calcu-
lated that the overall probability of misclassification in
our study is 4%, restricted to one or two false negatives.
Thus, we find it unlikely that the results in the RSV nega-
tive group are contaminated by misclassification of the
microbiological agent. For all variables studied, the results
in these two groups are so similar, that even a much larger
study would not be likely to detect differences.
Several studies have shown that hospitalisation for acute
RSV bronchiolitis in infancy is an important risk factor for
subsequent wheezing [24,25]. We show that hospitalisa-
tion for RSV negative bronchiolitis is an equal important
risk factor for subsequent wheezing as is RSV positive
bronchiolitis. The intensity of the host inflammatory
response, and not only the virus itself, is probably a major
determinant to whether or not bronchiolitis develops at
the time of infection. This has been well documented in a
recent study comparing infants with bronchiolitis due to
RSV and influenzavirus [26]. Also, a high frequency of
dual infection by RSV and hMPV has been reported in
infants with severe bronchiolitis receiving mechanical
ventilation [27].
The incidence of childhood asthma, when defined as
three or more episodes of wheezing ever during follow-
up, was in our study 51% in the hospitalised group and
14% in the control group. Correspondingly, as reported
by parents, 54% in the hospitalised group and 8% in the
control group were at age seven years consulting for
asthma with a family physician or a practicing paediatri-
cian. Our findings further support that hospitalisation for
early-life bronchiolitis, not only those due to RSV, is asso-
ciated with increased prevalence of childhood asthma, at
least up to age seven years [28,29].
The percentage of smokers among parents of the hospital-
ised children in our study was high. However, a high per-
centage of parents currently smoking was also recorded in
the control group. Exposure to tobacco smoke seemed not
to be an independent risk factor for childhood wheezing
in our study. Several studies have found parental smoking
to be an important risk factor for wheezing in early child-
hood but not in older children. In the Tucson Children's
Respiratory Study the greatest impact was found in chil-
dren under three years of age when mothers were smoking
during pregnancy [30].
No statistically significant differences were found between
the hospitalised group and the control group in current
prevalence of allergy or eczema in first order family mem-
bers and number of families with preschool siblings.
Heredity for asthma in the hospitalised group seemed to
be the only significant risk factor in first order family
members for childhood wheezing in our study. Several
other studies have shown that the prevalence of asthma
among family members of infants with acute viral bron-
chiolitis is slightly higher than in the general population
[31].
Subsequent readmissions after hospitalisation for acute viral  bronchiolitis during infancy Figure 1
Subsequent readmissions after hospitalisation for acute viral 
bronchiolitis during infancy.BMC Pediatrics 2005, 5:31 http://www.biomedcentral.com/1471-2431/5/31
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Early-life RSV bronchiolitis has in many studies been asso-
ciated with sustained impaired lung function. Our study
supports this by demonstrating significantly reduced test
results for several parameters in the hospitalised group
compared to the control group. Our results are in accord-
ance with a study from Noble et al in which the index chil-
dren had significantly reduced lung function at nine to ten
years of age [32]. According to a study by Sigurs et al
severe RSV bronchiolitis in infancy was significantly asso-
ciated with reduced lung function even at 13 years of age
[6].
Studies have shown that pulmonary function at birth of
newborns suffering from acute bronchiolitis later on dur-
ing infancy are reduced compared to pulmonary function
at birth of newborns not suffering from acute bronchioli-
tis later on during infancy [33,34]. This might indicate a
congenital pulmonal predisposition for bronchiolitis sus-
ceptibility and later obstructive lung disease. A significant
lower birth weight in the hospitalised infants in our study
might indicate that they had smaller lungs or delayed pul-
monal development compared to the controls.
Table 3: Wheezinga ever and current asthma in children hospitalised or not with acute bronchiolitis in infancy
Reported at child age seven years Hospitalised group Not hospitalised group
RS- (n = 22) RS+ (n = 35) Both (n = 57) Controls (n = 64)
≥3 episodes of wheezing ever during follow-upd 12 17 29 9
Current follow-up for asthma by a medical doctorb,e 10 21 31 5
Current medication for asthmac,e 81 22 0 5
a Wheezing ever in childhood treated by a family physician or a practicing paediatrician
b Current follow-up for asthma by a family physician or a practicing paediatrician
c Current asthma medication like β-2 agonists or inhaled corticosteroids
d P < 0.001 with chi square test between the hospitalised group and not hospitalised group
e P < 0.001 with chi square test between the hospitalised group and not hospitalised group
Table 4: Spirometry in children hospitalised or not with acute bronchiolitis in infancy
Age seven years Hospitalised group Not hospitalised 
group
FVC (liters) RS- (n = 22) RS+ (n = 35) 95% CIe Both (n = 57) Ctr (n = 64) 95% CIe
Predicteda 1.78 1.76 -0.12 0.15 1.77 1.82 -0.04 0.14
Before salbutamol 1.65 1.65 -0.17 0.17 1.65 1.75 -0.02 0.19
After salbutamolc 1.69 1.69 -0.16 0.17 1.69 1.81 0.004 0.22
Reversibilityb 2.5 1.9 -2.3 3.6 2.1 3.3 -9.3 3.2
FEV1 (liters)
Predicteda 1.51 1.50 -0.10 0.12 1.51 1.54 -0.04 0.11
Before salbutamolc 1.50 1.51 -0.16 0.13 1.50 1.64 0.05 0.23
After salbutamol 1.57 1.59 -0.16 0.11 1.59 1.70 0.03 0.20
Reversibilityb 4.9 5.6 -4.0 2.6 5.3 5.6 -3.5 3.9
FEF50 (liters/min)
Predicteda 2.34 2.33 -0.12 0.14 2.33 2.36 -0.07 0.13
Before salbutamold 1.92 1.99 -0.35 0.20 1.96 2.28 0.15 0.49
After salbutamold 2.17 2.34 -0.43 0.10 2.28 2.56 0.11 0.46
Reversibilityb 11.7 14.5 -10.0 4.3 13.4 9.6 -9.2 1.6
a According to European Respiratory Society 1993 Update
b Percent improvement 10 minutes after inhalation of 0.2 mg salbutamol
c P < 0.05 with independent samples T-test between the hospitalised group and not hospitalised group
d P < 0.01 with independent samples T-test between the hospitalised group and not hospitalised group
e 95% confidence interval (CI) of difference between meansBMC Pediatrics 2005, 5:31 http://www.biomedcentral.com/1471-2431/5/31
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Conclusion
Acute RSV bronchiolitis is a major health problem in our
region with a mean hospitalisation incidence for the
period 1993–2000 in infants of 23.6 per 1.000 [35]. Many
infants with acute viral bronchiolitis, not only those due
to RSV, will have episodes of recurrent wheezing, resub-
missions to hospital and reduced lung function, at least
up to age seven years. The results of the present study indi-
cate that host factors may be as important as the nature of
the infecting agent for the development of bronchiolitis
and later childhood wheeze and need further studies.
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